Kytopen announced a Series B financing round led by Telegraph Hill Partners, with participation from existing investors, as the company accelerates commercialization of its cellular engineering technology.
The funding will support Kytopen’s global expansion across the U.S. and Europe while driving broader adoption of its Flowfect® technology platform. As part of the investment, Telegraph Hill Partners will join Kytopen’s board of directors.
Kytopen specializes in non-viral, continuous flow cellular engineering, enabling rapid modification of cells at large scale. Its platform integrates mechanical, electrical, and chemical forces to engineer hundreds of billions of cells within minutes. The company’s Flowfect Tx® GMP and Flowfect Discover™ systems are designed to streamline the process from early-stage feasibility through clinical and commercial manufacturing.
The technology is built to integrate into closed GMP workflows and supports a wide range of cell therapy modalities. By improving scalability, consistency, and cost efficiency, Kytopen aims to advance next-generation cell therapies across multiple disease areas.
The company, headquartered in Cambridge, Massachusetts, has also established partnerships with biotechnology companies, contract development and manufacturing organizations, and medical centers focused on cell therapy innovation.
KEY QUOTES:
“Kytopen’s Flowfect technology has demonstrated the ability to genetically modify a broad range of therapeutic cell types in higher quantities, with better cell health and with lower cost than existing methods. Adoption of technologies like Kytopen’s will be essential to achieving broader community access to potentially curative cell therapies by lowering costs, shortening turn-around-time, and reducing variability.”
Matthew Mackowski, Chairman and Managing Director, Telegraph Hill Partners
“We welcome Telegraph Hill Partners to our investor base at this pivotal stage. With strong and growing customer demand, this investment enables us to scale globally while continuing to invest in the infrastructure needed to support our partners in delivering cost-effective, advanced cell therapies worldwide.”
Michael Chiu, CEO, Kytopen
